Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with multiple myeloma
- Patients who have already received 1 prior therapy with a proteasome inhibitor and lenalidomide and who were refractory to lenalidomide: added benefit not proven.
- Patients who have already received ≥ 2 prior therapies containing lenalidomide and a proteasome inhibitor and who showed disease progression under or after the last therapy: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2022-02-03 A G-BA decision was published.
Project details
- Project no.
- A21-101
- Commission
- Commission awarded on 01.08.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Daratumumab (multiple myeloma) - Addendum to Commission A21-101
Status: Commission completed
-
Dossier assessment
Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed